(Q41257177)

28 September 2017

title

Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study (English)

1 reference

28 September 2017

1 reference

1

Anat Gafter-Gvili

1 reference

28 September 2017

9

Irit Avivi

1 reference

28 September 2017

Elena Ribakovsky

2

1 reference

28 September 2017

Nadav Mizrahi

3

1 reference

28 September 2017

Abraham Avigdor

4

1 reference

28 September 2017

Ariel Aviv

5

1 reference

28 September 2017

Liat Vidal

6

1 reference

28 September 2017

Ron Ram

7

1 reference

28 September 2017

Chava Perry

8

1 reference

28 September 2017

Meirav Kedmi

10

1 reference

28 September 2017

Arnon Nagler

11

1 reference

28 September 2017

Pia Raanani

12

1 reference

28 September 2017

Ronit Gurion

13

1 reference

28 September 2017

publication date

5 May 2015

1 reference

28 September 2017

1 reference

28 September 2017

volume

57

1 reference

28 September 2017

issue

1

1 reference

28 September 2017

page(s)

63-69

1 reference

Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1046862

10.3109/10428194.2015.1046862

21 January 2018

Identifiers

DOI

1 reference

28 September 2017

1 reference